The DOI matches its Crossref record.
An Antiviral Soluble Form of the LDL Receptor Induced by Interferon
Abstract
Interferons, which induce several intracellular antiviral proteins, also induce an extracellular soluble protein that inhibits vesicular stomatitis virus (VSV) infection. This 28-kilodalton soluble protein was purified to homogeneity and identified by protein sequencing as the ligand-binding domain of the human 160-kilodalton low density lipoprotein receptor (LDLR). The existence of an antiviral soluble LDLR was confirmed by immunoaffinity chromatography with monoclonal antibody to LDLR. This soluble receptor mediates most of the interferon-triggered antiviral activity against VSV, apparently by interfering with virus assembly or budding, and not by inhibiting virus attachment to cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
LDLR and its family members such as VLDLR, apoER, and LRP1 undergo ectodomain shedding to release soluble forms into extracellular fluids such as cerebrospinal fluid and blood.
“LDLR and its family members such as VLDLR, apoER and LRP1 undergo ectodomain shedding to release their soluble forms into the extracellular milieu such as cerebrospinal fluid and blood12,29,30.”
From Membrane type 1 matrix metalloproteinase promotes LDL receptor shedding and accelerates the development of atherosclerosis (2021) · cites this paper as [12]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 34
- BEISIEGEL, U, MONOCLONAL-ANTIBODIES TO THE LOW-DENSITY LIPOPROTEIN RECEPTOR AS PROBES FOR STUDY OF RECEPTOR-MEDIATED ENDOCYTOSIS AND THE GENETICS OF FAMILIAL HYPERCHOLESTEROLEMIA, JOURNAL OF BIOLOGICAL CHEMISTRY 256: 11923 (1981). · DOI · Paper page
- BOUE, F, A PHASE-I TRIAL WITH RECOMBINANT INTERFERON-GAMMA (ROUSSEL UCLAF) IN ADVANCED CANCER-PATIENTS, CANCER IMMUNOLOGY IMMUNOTHERAPY 32: 67 (1990). · DOI
- 10.1126/science.3513311 · DOI · Paper page
- 10.1126/science.7680491 · DOI
- DOLEI, A, ANTIVIR RES 1: 367 (1981).
- ENGELMANN, H, A TUMOR NECROSIS FACTOR-BINDING PROTEIN PURIFIED TO HOMOGENEITY FROM HUMAN-URINE PROTECTS CELLS FROM TUMOR NECROSIS FACTOR TOXICITY, JOURNAL OF BIOLOGICAL CHEMISTRY 264: 11974 (1989). · DOI
- GAVIN, J.R., WATER-SOLUBLE INSULIN RECEPTORS FROM HUMAN LYMPHOCYTES, SCIENCE 178: 168 (1972). · DOI
- GERRARD, T.L., PRODUCTS OF STIMULATED MONOCYTES ENHANCE THE ACTIVITY OF INTERFERON-GAMMA, JOURNAL OF INTERFERON RESEARCH 9: 115 (1989). · DOI
- GOODING, L.R., VIRUS PROTEINS THAT COUNTERACT HOST IMMUNE DEFENSES, CELL 71: 5 (1992). · DOI
- HAWKINS, M, PHASE-I EVALUATION OF A SYNTHETIC MUTANT OF BETA-INTERFERON, CANCER RESEARCH 45: 5914 (1985).
- HORISBERGER, M.A., INTERFERON-INDUCED PROTEINS - IDENTIFICATION OF MX PROTEINS IN VARIOUS MAMMALIAN-SPECIES, VIROLOGY 180: 185 (1991). · DOI
- JONES, C.M., INTERFERON ACTIVATES MACROPHAGES TO PRODUCE PLASMINOGEN-ACTIVATOR, JOURNAL OF INTERFERON RESEARCH 2: 377 (1982). · DOI
- KERR, I.M., PPPA2'P5'A2'P5'-A - INHIBITOR OF PROTEIN-SYNTHESIS SYNTHESIZED WITH AN ENZYME FRACTION FROM INTERFERON-TREATED CELLS, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 75: 256 (1978).
- LANDSBERGER, D, A NONSENSE MUTATION IN THE LDL RECEPTOR GENE LEADS TO FAMILIAL HYPERCHOLESTEROLEMIA IN THE DRUZE SECT, AMERICAN JOURNAL OF HUMAN GENETICS 50: 427 (1992).
- 10.1038/330537a0 · DOI
- LUSTER, A.D., MOLECULAR AND BIOCHEMICAL-CHARACTERIZATION OF A NOVEL GAMMA-INTERFERON-INDUCIBLE PROTEIN, JOURNAL OF BIOLOGICAL CHEMISTRY 263: 12036 (1988). · DOI
- MASSARO, E.R., EFFECTS OF RECOMBINANT INTERFERON-ALPHA2 TREATMENT UPON LIPID CONCENTRATIONS AND LIPOPROTEIN COMPOSITION, JOURNAL OF INTERFERON RESEARCH 6: 655 (1986). · DOI
- MOSLEY, B, THE MURINE INTERLEUKIN-4 RECEPTOR - MOLECULAR-CLONING AND CHARACTERIZATION OF SECRETED AND MEMBRANE-BOUND FORMS, CELL 59: 335 (1989). · DOI
- NOVICK, D, MONOCLONAL-ANTIBODIES TO HUMAN INTERFERON-GAMMA - PRODUCTION, AFFINITY PURIFICATION AND RADIOIMMUNOASSAY, EMBO JOURNAL 2: 1527 (1983). · DOI
- NOVICK, D, SOLUBLE CYTOKINE RECEPTORS ARE PRESENT IN NORMAL HUMAN-URINE, JOURNAL OF EXPERIMENTAL MEDICINE 170: 1409 (1989). · DOI
- NOVICK, D, MONOCLONAL-ANTIBODIES TO HUMAN ALPHA-INTERFERON AND THEIR USE FOR AFFINITY-CHROMATOGRAPHY, JOURNAL OF IMMUNOLOGY 129: 2244 (1982). · DOI
- OHTSUKI, K, A RIBOSOMAL-PROTEIN MEDIATES EIF-2 PHOSPHORYLATION BY INTERFERON-INDUCED KINASE, NATURE 287: 65 (1980). · DOI
- OLSEN, E.A., CHANGES IN SERUM-LIPIDS IN PATIENTS WITH CONDYLOMATA ACUMINATA TREATED WITH INTERFERON ALFA-N1 (WELLFERON), JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 19: 286 (1988). · DOI
- ROSENZWEIG, I.B., PLASMA-LIPOPROTEIN CHANGES IN HUMANS INDUCED BY INTERFERON-BETA, ATHEROSCLEROSIS 67: 261 (1987). · DOI
- RUBIN, L.A., SOLUBLE INTERLEUKIN-2 RECEPTORS ARE RELEASED FROM ACTIVATED HUMAN LYMPHOID-CELLS INVITRO, JOURNAL OF IMMUNOLOGY 135: 3172 (1985). · DOI
- RUBINSTEIN, S, CONVENIENT ASSAY FOR INTERFERONS, JOURNAL OF VIROLOGY 37: 755 (1981). · DOI
- 10.1126/science.2160731 · DOI
- 10.1126/science.2988123 · DOI · Paper page
- VONHEIJNE, G, PATTERNS OF AMINO-ACIDS NEAR SIGNAL-SEQUENCE CLEAVAGE SITES, EUROPEAN JOURNAL OF BIOCHEMISTRY 133: 17 (1983). · DOI
- WALLACH, D, ENHANCED RELEASE OF LYMPHOTOXINS BY INTERFERON-TREATED CELLS, CELLULAR IMMUNOLOGY 76: 390 (1983). · DOI
- 10.1126/science.6324343 · DOI
- WEIL, J, A UNIQUE SET OF POLYPEPTIDES IS INDUCED BY GAMMA-INTERFERON IN ADDITION TO THOSE INDUCED IN COMMON WITH ALPHA-INTERFERON AND BETA-INTERFERON, NATURE 301: 437 (1983). · DOI
- 10.1126/science.2371562 · DOI
- YAMAMOTO, T, THE HUMAN LDL RECEPTOR - A CYSTEINE-RICH PROTEIN WITH MULTIPLE ALU SEQUENCES IN ITS MESSENGER-RNA, CELL 39: 27 (1984). · DOI · Paper page
Cited by
Sorted by citations
Khovidhunkit, W., Kim, M.-S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R., & Grunfeld, C. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r300019-jlr200 · Cited by 1,481
The generation and function of soluble apoE receptors in the CNS
Rebeck, G. W., LaDu, M. J., Estus, S., Bu, G., & Weeber, E. J. (2006) · Molecular Neurodegeneration · doi:10.1186/1750-1326-1-15 · Cited by 66
Alabi, A., Xia, X.-D., Gu, H.-M., Wang, F., Deng, S.-J., Yang, N., Adijiang, A., Douglas, D. N., Kneteman, N. M., Xue, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22167-3 · Cited by 63
The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms
Ndoj, K., Meurs, A., Papaioannou, D., Bjune, K., & Zelcer, N. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119082 · Cited by 17
Metadata
- Authors
- Fischer, D. G., Tal, N., Novick, D., Barak, S., & Rubinstein, M.
- Venue
- Science
- Published
- 1993-10-08
- Volume
- 262
- Issue
- 5131
- Pages
- 250-253
- ISSN
- 0036-8075
- 1095-9203
- Cited by
- 63
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
